PODD vs TNDM
PODD: Insulet Corporation provides tubeless, wearable insulin management technology that simplifies diabetes care for millions of patients worldwide. TNDM: Tandem designs intelligent, consumer-friendly insulin pumps with automated closed-loop technology to help people with insulin-dependent diabetes manage their condition with greater flexibility and less burden.
Side-by-side fundamentals
| Metric | PODD | TNDM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $158.93 | $16.91 | |
| Market cap as of 2026-07-23 | $11.3B | $1.2B | |
| P/E as of 2026-07-23 | 37.44 | n/a | |
| PEG as of 2026-07-23 | 1.23 | n/a | |
| Net margin as of 2026-07-23 | +10.4% | -9.2% | PODD higher |
| Gross margin as of 2026-07-23 | +71.0% | +54.9% | PODD higher |
| Operating margin as of 2026-07-23 | +14.6% | -8.2% | PODD higher |
| ROE as of 2026-07-23 | +17.4% | -68.3% | PODD higher |
| ROA as of 2026-07-23 | +7.5% | -10.0% | PODD higher |
| Debt / equity as of 2026-07-23 | 0.63 | 4.58 | PODD lower |
| Revenue growth (YoY) as of 2026-07-23 | +31.9% | +4.5% | PODD higher |
| Revenue CAGR (3y) SEC XBRL | +27.5% | +8.2% | PODD higher |
| Beta as of 2026-07-23 | 1.10 | 1.54 | |
| 1-year return as of 2026-07-22 close | -44.3% | +10.5% | TNDM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.